Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome

Clinical Infectious Diseases

Volumn 38, Issue 7, 2004, Pages 1030-1032

  Chen, Xiao Ping ^a,d   Cao, Yunzhen ^b,c  

^a GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^d Guangzhou Municipal Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINONE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PROTOCOL; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; EPIDEMIC; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL PERSONNEL; MORTALITY; NEPHROLITHIASIS; OUTCOMES RESEARCH; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SHORT COURSE THERAPY; VIRUS LOAD; VIRUS REPLICATION; ARTICLE; DISEASE TRANSMISSION; HONG KONG;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; HIV PROTEASE INHIBITORS; HONG KONG; HUMANS; PYRIMIDINONES; RITONAVIR; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 1842607741     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/386340     Document Type: Review

References (8)

1. Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361:1761-6.
2. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1977-85.
3. Chen XP, Li GH, Tang XP, et al. Lack of severe acute respiratory syndrome in 19 AIDS patients hospitalized together. J Acquir Immune Defic Syndr 2003; 34:242-243.
4. Chan KS, Lai ST, Tsui E, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9:399-406.
5. Yuen KY. Research outline of SARS in Hong Kong. In: Proceedings of the 2003 Prevention and Cure of SARS Seminar (Guangzhou, China). Guangzhou: Guangzhou Municipal Association of Science and Technology, 2003.
6. Boffito M, Arnaudo I, Raiteri R, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002; 16:2081-3.
7. Chu CM, Cheng VC, Hung IF, et al. The role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252-6.
8. Centers for Disease Control and Prevention. Severe acute respiratory syndrome - Singapore, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 405-11.